Intramammary infusion of beta1,3-glucan for prevention and treatment of Staphylococcus aureus mastitis.
Udder health problems associated with Staphylococcus aureus infections in dairy cows are difficult to control and antibiotics have limited effects. Lately, more interest has been directed towards ways to stimulate the innate immune mechanisms of the animal for better prevention and treatment of mastitis. The objectives of this study were to investigate if intramammary infusion at drying off with the immune modulator beta1,3-glucan can make the udder more resistant to experimental intra mammary S. aureus infection at this time, and to study if intramammary infusion of beta1,3-glucan into lactating udder quarters with chronic subclinical S. aureus infection can stimulate the clearing of the infection. Another aim was to evaluate the effect of beta1,3-glucan on the expression of major histocompatibility complex (MHC class II) on mammary leucocytes, measured by flow cytometry, during these circumstances. The results indicated a slight, but not statistically significant, positive effect of beta1,3-glucan at drying off on the clinical and anti-bacterial response to S. aureus infection, but no therapeutic effect of beta1,3-glucan treatment of udder quarters with chronic subclinical S. aureus mastitis. However, the proportion of MHCII+ milk lymphocytes tended to increase after glucan infusion in those udder quarters indicating a stimulation of the antigen presenting ability. To further evaluate a possible preventive effect of beta1,3-glucan infusion at drying off more studies are needed involving a larger number of animals.
Persson Waller
K
K
Department of Ruminant and Porcine Diseases, National Veterinary Institute, SE-751 89 Uppsala, Sweden. karin.persson.waller@sva.se
Grönlund
U
U
Johannisson
A
A
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D002417:Cattle; D003612:Dairying; D005260:Female; D005434:Flow Cytometry / Q000662:veterinary; D005936:Glucans / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D007263:Infusions, Parenteral; D007774:Lactation / Q000502:physiology; D007962:Leukocytes / Q000187:drug effects* / Q000378:metabolism; D008285:Major Histocompatibility Complex / Q000187:drug effects*; D008414:Mastitis, Bovine / Q000473:pathology / Q000517:prevention & control*; D013203:Staphylococcal Infections / Q000473:pathology / Q000517:prevention & control / Q000662:veterinary; D013211:Staphylococcus aureus / Q000472:pathogenicity; D047071:beta-Glucans
D000900:Anti-Bacterial Agents; D005936:Glucans; D047071:beta-Glucans; C033363:beta-1,3-glucan